Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][6][7]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [3]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on additive manufacturing for human organ transplantation [4]. Financial Performance - In Q4 2024, 3D Systems reported non-GAAP earnings-per-share of -$0.19, missing estimates by $0.08, with sales revenue of $111 million, a 3.4% year-over-year decline [8]. - For the full year 2024, sales were $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [8]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [9]. Market Response - Following the Q4 2024 results, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [8]. - After the Q1 2025 results, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [10]. Legal Allegations - The lawsuit alleges that during the Class Period, the company and its officers made materially false and misleading statements, including underestimating the impact of weakened customer spending and overstating the resilience of the business [6][7]. - The updated milestone criteria in the United Partnership were claimed to negatively impact the company's Regenerative Medicine Program revenue [7].

Core Viewpoint - Investors in 3D Systems Corporation have the opportunity to lead a securities fraud class action lawsuit due to alleged misrepresentations by the company regarding its financial health and business operations [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from August 13, 2024, to May 12, 2025, 3D Systems failed to disclose significant information, including the understatement of weakened customer spending's impact on the business and the overstatement of the company's resilience in tough industry conditions [2]. - It is alleged that updated milestone criteria in the United Partnership would adversely affect the revenue from the Regenerative Medicine Program [2]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses are encouraged to participate in the ongoing lawsuit before the lead plaintiff deadline of August 12, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against 3D Systems Corporation for violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased 3D Systems securities between August 13, 2024, and May 13, 2025 [2] - The complaint alleges that 3D Systems made false and misleading statements regarding the impact of weakening customer spending and the performance of its Regenerative Medicine Program [4] Group 2 - Investors are encouraged to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3][5] - The class in this case has not yet been certified, meaning that potential class members are not yet represented by an attorney [3] - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by August 12, 2025 [3][5]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, and sales revenue of $111 million, reflecting a year-over-year decline of 3.4% [6]. - For the full year 2024, the company reported sales of $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [6]. - In Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, more than doubling the loss from Q1 2024 [8]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [7]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, closing at $1.87 per share [9]. Allegations and Legal Context - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding customer spending and the impact on the company's business, as well as the revenue from its Regenerative Medicine Program [5]. - The firm encourages anyone with information regarding 3D Systems' conduct to come forward, including whistleblowers and former employees [11].